Professor Martin Walter, DZPG partner site spokeperson and Director of the Department of Psychiatry and Psychotherapy at Jena University Hospital, emphasizes: “The psychological symptoms associated with PCC are often distinct from known mental health disorders, although these can indeed occur more frequently in PCC. Many cases involve unique neuropsychiatric syndromes that require specialized care within the context of other physical impairments.”
With the launch of FEDORA, the DZPG takes a significant step toward investigating the physical (physiological) and neuropsychiatric (neurological and psychological) patterns of PCC. The project, lasting from November 2024 to October 2026 with BMBF funding of approximately 1.2 million euros, aims to create long-term profiles of PCC and to identify both somatic and neuropsychiatric patterns that will support more accurate diagnoses and personalized treatment plans in the future.
FEDORA uses innovative approaches, combining physiological data (such as sleep patterns, heart rate, and physical activity) with subjective evaluations provided by affected individuals, to develop a comprehensive picture of the illness. The project leverages sensor data and Ecological Momentary Assessment (EMA) data. These include continuous measurements of physiological parameters collected via wearable sensors, such as activity trackers and heart rate monitors, as well as situational assessments via smartphone, where participants report on their current status and well-being multiple times a day.
This methodology allows for a detailed, high-resolution timeline of symptoms and their fluctuations. “By integrating sensor data with EMA data, we can correlate objective and subjective parameters,” Professor Walter explains. “This enables us to identify specific patterns and create individual risk profiles.”
Researchers will analyze these diverse data sources—including studies on PCC, field data from specialized centers, and large epidemiological datasets encompassing over 250,000 healthy individuals and those affected by PCC—using artificial intelligence.
“Our goal is to identify specific patient subgroups and potential prognostic markers that indicate a higher risk for severe long-term effects,” Walter says. “This lays the groundwork for personalized prevention and treatment strategies.”
The findings are expected not only to enhance diagnostics and treatment for PCC but also to mitigate neuropsychiatric comorbidities such as depression, anxiety disorders, and post-exertional malaise (PEM).
“FEDORA contributes to ensuring that affected individuals receive appropriate support and treatment, helping to strengthen or rebuild their physical and cognitive resources,” states Professor Andreas Heinz, partner site spokeperson and founding spokeperson of DZPG.
Professor Andreas Meyer-Lindenberg, also a founding spokesperson of the DZPG, adds, “With FEDORA, the DZPG is taking an important step towards a better long-term understanding of PCC and the improved care of those affected, thereby supporting not only patients but also their families. This research represents a key element in combating the growing societal impact of Long/Post-COVID.”
The close alignment of FEDORA with another project funded by the Federal Ministry of Health (BMG) provides a concrete perspective for translating FEDORA's insights into improved clinical care for PCC patients. In the REMIT project ("Remote Monitoring & Intervention for Optimized Care of Post-COVID Condition"), an interdisciplinary DZPG team led by Professor Nils Opel (DZPG Jena site) collaborates with industry partners to apply FEDORA’s findings in innovative digital diagnostic and care approaches for PCC patients. This project will develop both technical solutions and complementary measures, such as training for healthcare providers to effectively integrate digital tools in various care settings—from primary care practices to specialized university post-COVID centers.
Source: DZPG
On 7 and 8 November 2024, the second Science & Career Day of the German Centres for Health Research (DZG) took place at the German Institute of Human Nutrition (DIfE) in Potsdam. The event provided an inspiring forum for early career scientists to engage in interdisciplinary exchange and networking.
The DZG Science & Career Day 2024 was dedicated to translational medical research under the motto ‘From the lab to life - How you can translate your research into medical innovations’. Following the welcome by Prof Annette Schürmann (DZD/DIfE) and Dr Katharina Eulenburg (DZHK), three renowned scientists from different DZGs presented their work on the topic of cell and gene therapies. Prof. Nico Lachmann from the German Centre for Lung Research (DZL) gave an impressive presentation on how his research on macrophages (specialised immune cells), derived from human induced pluripotent stem cells, is aimed at the treatment of tissue damage and cancer. Prof Annette Künkele-Langer from the German Consortium for Translational Cancer Research (DKTK) introduced the audience to the development and clinical application of ‘chimeric antigen receptors’ in cancer immunotherapy. Subsequently, Prof Henrik Semb from the German Centre for Diabetes Research (DZD) highlighted advancements in the use of human embryonic stem cells for diabetes therapy, vividly illustrating the
complex challenges in bridging the gap between basic research and clinical application.
The panel discussion, moderated by Prof Boris Fehse (DZIF), provided further insight into successful translation of basic research into medical applications within the DZG framework and addressed current challenges. In addition to the three speakers from the previous session, Dr Ute Petereit (Federal Ministry of Education and Research) and Prof Schürmann joint the discussion. Prof Schürmann emphasised how the DZGs effectively utilize their networks and synergies: ‘Bringing together experts with diverse backgrounds - basic science, clinical science, epidemiology - is what makes the DZG so successful’. Dr Petereit reinforced this point, adding: ‘The DZGs hold a very important position in translational health research in Germany’. Alongside these successes, challenges were also discussed. Increasing interaction between the DZGs and advancing timely framework agreements for intellectual property and industry partnerships were highlighted as priorities. On a positive note, specific funding programmes for young medical doctors in research and flexible career paths for early career scientists have already been successfully implemented. However, the participants noted that further incentives are needed to retain talent in academic research in the long term.
Another central theme of the discussion was the importance of a patient-centred perspective. Prof Lachmann shared his personal experience: ‘Always keeping the patients’ needs in focus fuels the passion for research’. Prof Semb (DZD) added: ‘Translational research requires someone who sees the bigger picture and keeps everybody working toward the need of patients as a common, higher goal’. There was consensusthat the key to success lies in personal enthusiasm for the chosen research topic. Prof Künkele-Langer (DKTK) succinctly stated: ‘Find something that is really fun. You need a topic you can immerse yourself in and that excites you’. Prof Fehse (DZIF) echoed this sentiment: ‘You will only succeed if you burn for the project’.
The following poster session provided early career scientists the opportunity to present and discuss their research. Karin Bodewits from NaturalScience.Careers also offered valuable feedback on poster design. During the networking dinner that followed, some early career scientists gave engaging threeminute pitches, sparking lively conversations.
The second day of the Science & Career Day began with the lecture ‘From scientist to entrepreneur’ by Dr Heidi Zinecker and Dr Michael Karle (Ascenion GmbH), which dealt with patenting processes and intellectual property. In the subsequent workshop ‘Strategic Networking’, moderated by Karin Bodewits, Prof Henriette Kirchner (DZD) and Prof David Capper (DKTK) shared valuable personal insights into the importance of networking in science. Participants received practical tips on how to expand their network and use LinkedIn effectively. The event concluded in the afternoon with warm thanks to the organisers - until next year!
More informationen and picture gallery
Source: DZL
International Lung Researchers, led by DZL Scientist Jürgen Behr (DZL Location Munich, CPC-M), reach consensus on fundamental classifications for the treatment of Interstitial Lung Diseases. In an article published in the American Journal of Respiratory and Critical Care Medicine, experts (including Margaret Salisbury, Vanderbilt University Medical Center, Nashville/Tennessee, and Athos Wells, Brompton Hospital and Imperial College, London) have also addressed and filled several knowledge and evidence gaps.
In interstitial lung disease (ILD), there are numerous different disease trajectories, complicating decisions about anti-inflammatory and antifibrotic treatment strategies. Often, these decisions are based on limited scientific evidence. While it is assumed that the underlying mechanisms of inflammation and fibrosis play a key role, they are not yet fully understood. To make the best individual treatment decisions, various factors must be considered. However, which of these factors should take priority in different clinical scenarios can vary significantly. A particular problem is the lack of randomized controlled trials (RCTs) that could provide guidelines to properly assess these differences at the initial presentation of patients.
To better integrate the complex information on disease mechanisms, a multidisciplinary discussion (MDD) is likely the best approach. This aims to help identify meaningful treatment goals by individually assessing the courses of inflammation and fibrosis. In certain forms of ILD, such as organizing pneumonia with overlapping fibrosis, therapy could lead to a partial reversal of the disease. In contrast, with primary and secondary fibrotic NSIP (nonspecific interstitial pneumonia), stabilizing the disease progression should be the primary goal.
It is different for idiopathic pulmonary fibrosis (IPF), where the main objective in most cases is to slow the disease’s progression. Here, new biomarkers and other data could support decision-making. A central issue in the treatment of fibrotic ILDs such as IPF is that the focus is heavily on antifibrotic therapies, while the role of the immune system is often overlooked. This could miss important contributions to the disease’s development. Therefore, there is an urgent need to investigate the role of immune cells in the lungs of ILD patients more intensively. New technologies, such as spatially resolved single-cell RNA analysis, could help discover new pathways for future, personalized therapies. By better understanding the immunological and fibrotic mechanisms, targeted treatment methods could be developed in the future, similar to recent successes in asthma treatment.
The role of artificial intelligence (AI) algorithms in predicting lung function loss needs further investigation. New high-resolution imaging technologies, such as endobronchial optical coherence tomography (OCT) and confocal laser endomicroscopy, allow for the visualization of fine changes in the lungs. These procedures could help diagnose patients with unclear findings on conventional CT scans. They are capable of distinguishing between different tissue types, such as scar tissue (fibrosis) and inflammation, which is especially important for patients who cannot undergo lung biopsies. Experts see great potential in these technologies for the future diagnosis and treatment of lung diseases.
Original publication: The Role of Inflammation and Fibrosis in Interstitial Lung Disease Treatment Decisions. Behr, J., Salisbury, M.L., Walsh, S.L.F., et al. Am J Respir Crit Care Med. 2024 Aug 15;210(4):392-400.
Source: DZL
Treatment with immune checkpoint inhibitors has significantly improved the survival rate of people with advanced-stage malignant melanoma. However, whether patients respond to the therapy can only be checked by radiological imaging around three months after the start of therapy. A relatively new blood test - the liquid biopsy - can provide information on whether the tumor is receding at a much earlier stage. In a study, researchers from Tübingen were able to show that liquid biopsy can supplement complex radiological diagnostics for skin cancer.
Immune checkpoint inhibitors (ICI) are antibodies that strengthen the body's own immune system in the fight against cancer. Since the approval of ICI for the treatment of advanced malignant melanoma, the ten-year survival rate of patients has more than doubled. Not only inoperable metastases can be treated with ICI. For a few years now, ICIs have also been used after the surgical removal of high-risk melanomas or metastases. The risk of recurrence of the disease (relapse) can thus be minimized.
However, ICIs can cause serious health problems as a side effect. This is because the natural brake on the immune system is released, allowing immune cells to attack the body's own tissue or healthy organs. As only around one in two patients responds to the therapy, it is important to recognize as early as possible who the therapy is working for and who is not. In order to determine whether and how the cancer is developing, staging diagnostics are carried out using whole-body computed tomography (CT) or PET-CT. In contrast to conventional whole-body CT, PET-CT can provide additional information about the metabolic activity of the tumor tissue. ICIs need time to develop their full effect. Doctors therefore only know whether the tumor tissue is responding to the therapy around three months after the start of treatment.
In parallel to staging diagnostics, researchers from Tübingen, including those from the German Cancer Consortium (DKTK), have therefore carried out a study to monitor tumors using a new method known as liquid biopsy - a blood test that can be used to detect and evaluate tumor DNA circulating in the body. Liquid biopsy is already routinely performed for breast and lung cancer. Liquid biopsy is currently only used for black skin cancer in individual cases and is not reimbursed by statutory health insurance companies in routine care. However, liquid biopsy is becoming increasingly relevant. “In contrast to PET-CT, it is significantly cheaper and can be repeated several times in a short space of time, for example every month. Just a few weeks after starting treatment with ICI, the test shows whether the amount of tumor DNA in the blood is decreasing or increasing,” explains Prof. Dr. Andrea Forschner, Head of the Melanoma Outpatient Clinic at the University Dermatology Clinic in Tübingen. Together with Dr. Christopher Schroeder from the Institute of Medical Genetics and Applied Genomics, Forschner conducted a study to investigate whether liquid biopsy indicates that patients are responding to ICI. “We wanted to know how reliably the liquid biopsy indicates that the therapy is working - or that recurrences can be detected,” explains Forschner. New bioinformatic analysis methods, developed in the group of Prof. Dr. Stephan Ossowski from the Institute of Medical Genetics and Applied Genomics, make it possible to identify the smallest amounts of tumor DNA in blood plasma.
Half of advanced metastatic melanoma patients with inoperable metastases live longer than ten years after diagnosis thanks to ICI therapy. There are now some patients in whom all metastases have even disappeared. “The radiation exposure from radiological diagnostics should therefore be kept as low as possible in order to minimize the risk of long-term consequential damage,” emphasizes melanoma researcher Forschner. The results of the study have now been published in the journal Nature Communications.
In the study, the research team used a new liquid biopsy procedure, which was carried out on 87 melanoma patients every few weeks. This involved examining not just a single genetic change in the tumor in the blood test, but up to 30 different ones. “With the new method, it was possible to detect even very small amounts of tumor DNA in the blood, which is particularly important for the regular monitoring of possible recurrences,” explains Schroeder. The results of the liquid biopsies were compared with those of the PET-CT.
“We were able to show that a regular liquid biopsy can tell us earlier than PET-CT whether a patient is responding to ICI or not,” explains Forschner. In particular, patients who do not respond to ICI therapy but develop side effects could be switched to other therapies earlier. All tumor-free patients in whom the development of a recurrence was monitored remained negative in both the liquid biopsy and PET-CT during the study period, which indicates the high reliability of the liquid biopsy. In future, these patients could be spared the need for closely timed radiological diagnostics thanks to the blood test, and radiological diagnostics could be offered at an early stage in the case of abnormal liquid biopsies.
The study team is currently working on testing monitoring using liquid biopsy in further studies so that it can be used for all melanoma patients in the future. In addition, monitoring would have to be reimbursed by health insurance companies. Currently, apart from individual cases, funding is only possible through research funds. The study was refinanced by funding from the Immuno-Oncology Foundation.
Original publication: Tumour-informed liquid biopsies to monitor advanced melanoma patients under immune checkpoint inhibition. Schroeder, C., Gatidis, S., Kelemen, O. et al. Nat Commun 15, 8750 (2024).
Source: DKTK
The Long COVID Medical Association and the Federal Ministry of Health invite you to the 3rd Long COVID Congress in Berlin on November 25, 2024. Research findings from the German Centers for Health Research will also be presented. The event, with the participation of Federal Minister of Health Prof. Dr. Karl Lauterbach, is dedicated to the overarching question: “Needs-based care for post-infectious diseases - a generational problem?”.
The aim is an intensive exchange on the latest research projects and results, diagnostic procedures and therapeutic approaches in order to continue to guarantee and improve the care of those affected in the future. A particular focus this year will be on research and care for affected children and adolescents. Participants at the congress can choose from various themed rooms in which different research groups will present and then discuss current projects.
Among others, the following will be presented: “Diagnostics - harmonization or specialization” as well as “Therapy: what must be given, what can be given, what is coming soon?” and “Registers, data models and databases: what is available? What else is needed?”
Date: November 25, 2024
Time: 9.30 am – 6.00 pm
Location: Tagungswerk, Lindenstr. 85, 10969 Berlin
Organizer: Long COVID Medical Association and the Federal Ministry of Health
Conference management: Dr. Daniel Vilser, Prof. Dr. Rembert Koczulla
Conference language: German
Education points: CME points applied for at the Berlin Medical Association
Livestream: For the main program from 9.30 - 11.00 am and 4.00 - 6.00 pm. A link will be published online in good time.
Registration: https://long-covid-kongress-2024.anmeldung-events.de (Registration deadline for specialist participants: 20.11.2024)
Researchers from DZNE and Otto von Guericke University Magdeburg have identified individuals with increased risk for dementia using mobility data, recorded during a smartphone-based wayfinding task on the university campus. The findings, reported in the journal PLOS Digital Health, show the potential of smartphone data, collected in conditions close to everyday life, for the early detection and monitoring of Alzheimer’s disease. The study included 72 adults; about a third of them with subjective cognitive decline (SCD), a condition that is a known risk factor for dementia.
Alzheimer’s disease usually develops unnoticed over years and eventually leads to dementia. To date, there is no cure. “Currently, Alzheimer’s is often treated too late to ensure effective therapy. Even the new antibody drugs that are being much discussed at the moment only work if they are given at an early stage. Thus, we need to be able to diagnose the disease earlier, when symptoms are still mild. This requires advances in diagnostics,” says Dr. Anne Maass, a research group leader at DZNE and guest professor at the University Magdeburg. With colleagues, she now tested a novel approach to assessing problems in spatial navigation, as one of the first potential symptoms of Alzheimer’s disease.
“Our study is based on a kind of scavenger hunt where participants had to find pre-specified points-of-interest. For this, they used a smartphone equipped with a special app that we developed,” explains Dr. Nadine Diersch. The neuroscientist initiated the research project at DZNE several years ago and today works in the private sector, but continues to be associated with DZNE as a guest researcher. “We found that certain app data allow to reliably identify people with an increased risk for dementia,” she says. “This shows that digital technologies, like mobile apps, offer completely new possibilities to assess cognitive functioning under realistic, low-threshold conditions. In the future, this, may help detect subtle cognitive changes and thus harbingers of dementia earlier than today.”
In total, 72 women and men between the ages of their mid-twenties and mid-sixties participated in the study. Of the 48 older individuals, 23 were diagnosed as SCD patients. People with this condition perceive a loss of mental capacity, which, however, cannot be detected by conventional neuropsychological tests. These individuals do not inevitably develop dementia. However, it has been shown that they are at an increased risk. All study participants were instructed to independently find several buildings on the medical campus of the University Magdeburg, guided by the app, while their movement patterns were tracked by GPS. “Our participants had similar knowledge of the campus area and they were all experienced in using smartphones. We also practiced using the app beforehand,” explains Jonas Marquardt, first author of the study and PhD student in the research group of Anne Maass.
During the task, which every study participant had to perform individually, five buildings had to be visited in a row along a route of about 800 meters. The app served as a pacemaker: It displayed a map with the current position and the next destination, including a photo of it. However, the map disappeared as soon as a participant started walking. “The participants had to memorize the layout of the streets, their position and their destination, and then follow their sense of direction and spatial memory,” Marquardt says. “If they got lost, they could press a help button in the app. The map, their position and their destination would then briefly reappear.” The researchers leveraged the GPS data to generate individual mobility profiles and other information.
In most cases, the participants reached the five destinations in less than half an hour. “Overall, the younger participants performed better. On average, they walked shorter distances and generally did not use the help function as often as the older ones,” says Marquardt. The differences between the older adults with and without SCD were mainly reflected in the number of so-called orientation stops. Jonas Marquardt explains: “Older adults with SCD briefly stopped during walking more often, presumably to orient themselves, than older adults without SCD. In fact, we were able to identify participants with SCD based on this parameter.”
So far it is unclear why people with SCD stand out in this regard. “We found that they tend to hesitate more at intersections in particular. This suggests that certain decision-making processes are altered. However, the data are not yet conclusive,” Nadine Diersch explains. “Nevertheless, the results of our study are a promising proof of concept. They show that smartphone data can help detect subtle signs of cognitive decline in realistic contexts.” The scientist considers this an opportunity for early detection and early treatment of dementia: “I could imagine such apps being used in the future to identify people at risk and then decide whether further testing or already therapy is needed.”
Source: DZNE
In Nature Reviews Cardiology, DZHK researchers shed light on various mechanisms in the interaction between the gut microbiome and thromboses. This could lead to new approaches for the prevention and treatment of thrombosis and associated cardiovascular diseases.
A new scientific review in Nature Reviews Cardiology shows that the gut microbiome influences the development of thrombosis in several ways. In addition to the production of trimethylamine-N-oxide (TMAO), various bacterial metabolites and inflammatory processes contribute to thrombus formation. One example is the bacterial conversion of choline and carnitine from foods such as red meat into TMAO, which is known to promote platelet activation.
In addition, studies show that the gut microbiota influences the integrity of the intestinal barrier (Commensal bacteria weaken the intestinal barrier by suppressing epithelial neuropilin-1 and Hedgehog signalling | Nature Metabolism). When this barrier is disrupted, endotoxic substances can enter the bloodstream and trigger inflammatory reactions that contribute to thrombosis formation. This leads to an increased systemic level of inflammation, which also increases the blood's tendency to clot.
In addition, short-chain fatty acids (SCFAs), which are produced by certain intestinal bacteria, play a role in regulating inflammation and stabilising the endothelium, which in turn can modulate the coagulation processes. Another example is the bacterial influence on bile acids, which alters liver metabolism and blood lipid levels. Imbalances in these mechanisms could increase the risk of cardiovascular complications such as thrombosis.
‘Our results show that the gut microbiome has a far-reaching influence on the vascular system and thrombosis. Understanding the microbial mechanisms that promote thrombosis opens up promising possibilities for preventive therapies targeting microbial diversity and influencing microbial metabolites,’ explains Christoph Reinhardt, last author of the study from the Center for Thrombosis and Haemostasis (CTH) at the University Medical Center Mainz.
These research results open up new perspectives for therapeutic measures, including targeted probiotics, prebiotic nutrition or drugs that could regulate the influence of specific bacteria and their metabolites on the coagulation system. These new approaches could help to fundamentally improve the prevention and treatment of thrombosis and related cardiovascular diseases.
Original publication: The gut microbiota in thrombosis. Khuu, M.P., Paeslack, N., Dremova, O. et al. Nat Rev Cardiol. 2024 Sep 17.
Source: DZHK
The protective effect of established COVID-19 vaccines is initially very robust, but wanes relatively quickly. This limitation imposes a need for periodic booster shots, which drives vaccine hesitation. In contrast, an innovative vector vaccine developed at the Helmholtz Centre for Infection Research (HZI) presents a compelling alternative. It elicits prolonged immune response in animal models, and maintains its efficacy over extended time. The concept employs an animal cytomegalovirus (MCMV; murine cytomegalovirus) as the vector that expresses and delivers the coronavirus spike protein information. Crucially, this vector poses no threat to humans, enhancing the vaccine's safety profile.
In 2022, researchers from the department “Viral Immunology” headed by Prof. Luka Cicin-Sain at the Helmholtz Centre for Infection Research reported on the novel vector vaccine for the first time. The promising immunogenic profile of the MCMV-based vaccine has now been shown to protect against disease. A recent publication, which involved other national and international research institutions such as the German Center for Infection Research (DZIF), the Max Delbrück Center in Berlin and the University of Rijeka in Croatia, demonstrates long-lasting and broad immune responses and antiviral protection in the mouse model.
Using an animal cytomegalovirus that cannot replicate in human cells as a vector is a clever move, because it combines high immunogenicity of a natural infection with the safety of a non-replicating vector. In vector vaccines, viruses are used as vehicles to introduce building blocks of the pathogen against which the vaccination is directed into the human body. In vaccines against COVID-19, the gene for the blueprint of the spike protein that anchors the coronavirus to the host cells is integrated into the vector viruses.
There are reasonable concerns about the safety of vaccines based on some vector viruses. Human viruses that are used as vectors have to be attenuated by genetic modifications. The MCMV, however, can be used as is, because cytomegaloviruses are highly host-selective. This means that the MCMV can only replicate in mouse cells, but not in human ones, as two of the first authors, Dr. Kristin Metzdorf and Dr. Henning Jacobsen, explain. For this reason, among others, MCMV is ideal as a vector for vaccines.
The researchers see the big advantage in the long-lasting vaccination response that can be achieved with the MCMV vaccine after just one dose. Using an animal model, it was shown that the concentration of antibodies available for defence against the pathogen in the event of a subsequent infection with the SARS-CoV-2 coronavirus remains stable over a period of six months after vaccination. Results from research colleagues at the University of Rijeka in Croatia suggest that the protective effect lasts even longer.
The immune system takes a two-pronged approach to fighting pathogens: firstly, highly specific antibodies are formed that are directed against defined structures of the microbe and render it harmless. The second track consists of the mobilization of immune cells that specifically recognize infected cells and actively fight the pathogens in them. So-called CD8+ T cells play the central role here. After vaccination with the MCMV vaccine against COVID-19, the antibodies circulating in the blood and CD8+ T cells directed against infected cells are permanently present and ready for action.
Research about the reasons for the lasting protective effect of MCMV vaccines are ongoing. A plausible explanation is that cytomegaloviruses restimulate immune cells for a long time by hiding in a mostly dormant mode in cellular niches of their host, a state known as latency. Only when the host organism's immune defences weaken the viruses switch to the active mode, replicate and spread, causing signs of illness. The MCMV vector viruses presumably will also try to settle in the human organism, but because humans are not the right host for them, reactivation does not work. The human immune system does not allow murine viruses to reappear in the blood and takes action against them as soon as they produce proteins and before infectious particles are formed. In this way, according to the theory, the immune defence is repeatedly stimulated and the vaccination effect is maintained.
And there is one more thing. Coronavirus immunity does not only wane due to the loss of immune cells, but also because the viruses mutate to escape immune recognition by antibodies. MCMV vaccines keep this evolution in check, at least in part. The researchers used the spike gene of the very first SARS-CoV-2 variant for the new vaccine. Upon vaccination with the MCMV vaccine, specific antibodies were initially formed against the original spike protein, which was expected. However, some months after vaccination, antibodies against SARS-CoV-2 variants such as the Omicron started to form and increase in number. This is probably due to a mechanism of the immune system that serves to increase resistance to attackers through mutations (genetic changes) in the relevant immune cells. According to the researchers, the fact that this mechanism is particularly well supported by the MCMV vaccine is a further advantage of this technology.
The favourable all-round profile of the MCMV vector is completed by its high capacity to take up foreign genes. These are exchanged for virus genes that are not essential for the integrity of the virus. Theoretically, it is possible to introduce several different genes of a pathogen into the MCMV at the same time and thus increase the vaccination effect or the activity spectrum against variants. It is also conceivable to use this vector to produce combination vaccines that provide immunity against various diseases in one go. The combined vaccination against COVID-19 and influenza would be a useful example.
Original publication: A single-dose MCMV-based vaccine elicits long-lasting immune protection in mice against distinct SARS-CoV-2 variants. Metzdorf, K., Jacobsen, H., Kim, Y. et al. Front. Immunol. 25 July 2024.
Source: DZIF
Researchers led by DZHK scientist Alexander Bartelt at LMU University Hospital have discovered a new switch that controls thermogenesis in mitochondria.
Special fat cells known as brown adipocytes help maintaining body temperature by converting calory-rich nutrients into heat. This protects from gaining excess weight and metabolic disorders. An international team of researchers led by Professor Alexander Bartelt from the Institute for Cardiovascular Prevention (IPEK) has deciphered a new mechanism that increases respiration and metabolic activity of brown fat cells. The researchers hope that this discovery will lead to novel approaches utilizing brown fat against metabolic diseases. Their results were recently published in The EMBO Journal.
The activation of fat-burning cells makes people lose weight. When it is cold, brown adipocytes extract their fuel from storage fat, as thermogenesis requires a lot of calories. “People who train their brown fat through regular cold exposure are thinner and less prone to developing diabetes and cardiovascular diseases,” says Bartelt. Brown fat cells are particularly rich in mitochondria, the power plants where cellular respiration takes place. However, science does not yet sufficiently understand how brown fat cells boost metabolism such that new therapies could be developed.
The molecular trick of brown fat cells is uncoupling protein-1, which facilitates that heat is generated instead of ATP, the conventional product of cellular respiration. “The high metabolic activity of brown fat cells must also influence the production of ATP,” says Bartelt, “and we hypothesized that this process would be regulated by cold.” Together with Brazilian colleagues from São Paulo, the researchers identified “inhibitory factor 1,” which ensures that ATP production is maintained instead of thermogenesis. When temperature goes down, the levels of inhibitory factor-1 fall and thermogenesis can take place. When artificially increased, inhibitory factor 1 disrupts the activation of brown fat in the cold.
These findings were obtained in isolated mitochondria, cultivated cells, and an animal model. “While we have found an important piece of the puzzle for understanding thermogenesis, therapeutic applications are still a long way off,” explains Dr. Henver Brunetta, who conducted the study. According to the authors, most people use their brown fat too little and it becomes dormant. The new study results indicate that there are molecular switches that allow mitochondria of brown fat cells to work better. Bartelt and his colleagues plan to build on this discovery. “Ideally, we’ll find new ways, based on our data, to also restore the fitness of mitochondria in white fat cells, as most people have plenty if not too many of them,” concludes Bartelt.
Original publication: IF1 is a cold-regulated switch of ATP synthase to support thermogenesis in brown fat. . 2024 Sep 16.
Source: DZHK
Using infrared light and machine learning, researchers from the attoworld team have developed a method to investigate the health status of a population. Scientists from Ludwig-Maximilians-Universität Munich, the Max Plack Institute of Quantum Optics and the team of DZD Professor Annette Peters from Helmholtz Munich with the KORA study were involved.
A single drop of blood providing comprehensive health insights within minutes? Thanks to recent scientific advancements, this vision may become reality. Scientists from the BIRD team led by Mihaela Žigman at Ludwig-Maximilians-Universität (LMU) and the Max Planck Institute of Quantum Optics (MPQ), in collaboration with Helmholtz Munich, have developed a health screening tool that uses infrared light and machine learning to detect multiple health conditions with just one measurement.
Infrared spectroscopy, a technique that employs infrared light to analyze the molecular composition of substances, has been a foundational tool in chemistry for decades. It’s like giving molecules a fingerprint that can be delivered by a specialized machine called a spectrometer. When applied to complex biofluids like blood plasma, this physico-chemical technique can reveal detailed information about molecular signals, making it a promising tool for medical diagnostics. Despite its long-standing use in chemistry and industry, infrared spectroscopy has not been established nor integrated into the canon of medical diagnostics.
Led by Mihaela Žigman, a team of scientists from the BIRD group at LMU and MPQ initiated an effort to tackle this issue. Having previously established a method for measuring human plasma, they collaborated with Annette Peters' team from Helmholtz Munich to pioneer infrared molecular fingerprinting on a naturally diverse population. This involved measuring blood from thousands of individuals in the KORA study, a comprehensive health research project established in Augsburg, Germany. Randomly selected adults were chosen as a representative scenario for a naturally variable population and were recruited for medical examinations and blood donations.
What is the value of the current work? The existing KORA study got a new value as it got tested from a fresh perspective and served a new purpose: More than 5.000 blood plasma samples were measured using Fourier transform infrared (FTIR) spectroscopy. Tarek Eissa and Cristina Leonardo of the BIRD team at LMU analyzed the blood samples from the KORA study using infrared light to obtain molecular fingerprints. The team applied machine learning to analyze the molecular fingerprints and correlated them with medical data. They discovered that these fingerprints contain valuable information that enables rapid health screening. A multi-task computer algorithm that is now capable of distinguishing between various health states, including abnormal levels of blood lipids, various changes in blood pressure, seeing type-2 diabetes but also spotting even pre-diabetes, a precursor to diabetes often undetected.
Interestingly, the algorithm could also single out individuals who were healthy and remained healthy over the investigated years. This was very significant for two reasons: firstly, most people in any random population experience abnormal health changes and given that we are all different, as well as that we all change over time, it is all but trivial to find fully healthy individuals. Secondly, many individuals suffer from multiple conditions in various combinations. Traditionally, doctors would need a new test for each disease. However, this new approach doesn’t just pinpoint one condition at a time - it accurately identifies a range of health issues. This machine learning-powered system not only identifies healthy individuals but also detects complex conditions involving multiple illnesses simultaneously. Moreover, it can predict the development of metabolic syndrome years before symptoms appear, providing a window for interventions.
This study lays the groundwork for infrared molecular fingerprinting to become a routine part of health screening, enabling doctors to detect and manage conditions more efficiently, the researchers say. This is especially important for metabolic disorders like cholesterol abnormalities and diabetes, where timely and effective interventions can significantly improve outcomes. However, the potential applications of this technology extend even further. As researchers continue to refine the system and expand its capabilities, by means of technology development and the establishment of these in the context of clinical studies, there will be even more health conditions and their combinations added to the diagnostic repertoire, the researchers hope. This could lead to personalized health monitoring, where individuals regularly check their health status and catch potential issues long before they become serious.
In conclusion, the combination of infrared spectroscopy with machine learning is set to transform health diagnostics, the researchers believe. With a single drop of blood and infrared light, there will be a powerful new tool to keep tabs on our health, catching problems more efficiently and potentially improving healthcare globally.
Original publication: Plasma infrared fingerprinting with machine learning enables single-measurement multi-phenotype health screening. Tarek, E., Cell Reports Medicine. 2024;5(7):101625.
Source: DZD
"Stigma is based on the fact that a person is not judged as an individual, but based on the characteristics attributed to their group," explains Rüsch. "Typical opinions are, for example: 'Mentally ill people are incompetent, dangerous or to blame'." The term "second illness" has become established among experts to describe the burden of stigmatisation, as it is often more stressful for those affected than the illness itself. It can significantly reduce quality of life by leading to social isolation and, worsened health and even the avoidance of effective treatment. Many sufferers internalise the prejudice, which is called self-stigma: "Because I am mentally ill, I must be incompetent." The problem is enormous: "A worldwide study, in which Germany and Switzerland also took part, surveyed over 1,000 people with schizophrenia and around 800 people with depression. Around 80 per cent stated that they had experienced stigmatisation," says Rüsch. Edmund Bornheimer, member of the Trialogue Centre Council of the DZPG, adds: "Due to stigmatisation, disclosing the illness can still have negative consequences today. I have experienced this several times in a professional context."
Discrimination doesn't just affect those affected themselves: "Relatives also continue to experience painful stigmatisation in everyday life. In particular, relatives of people with severe mental illnesses have an increased risk of developing mental health problems themselves," says Heike Petereit-Zipfel from the Federal Association of Relatives of People with Mental Illness (BApK) and also a member of the Trialogue Centre Council.
The DZPG has not only set itself the task of improving the mental health of the population but also of reducing the stigma of mental illness. The group programme "Standing by yourself with dignity" (IWS) at the Department of Psychiatry and Psychotherapy II of the University Medical Centre Ulm at Günzburg District Hospital (BKH) helps people with mental illness to make a considered decision about whether or not to disclose their illness. This is a key decision in dealing with stigma and self-stigma. IWS is run by trained peers, i.e. people who have experienced the illness themselves.
What research already knows is that awareness campaigns that provide information about mental illness have proven to be less effective in reducing stigma. Rüsch points to more effective means: "These include programmes that promote direct social contact between people with and without mental illness and enable individual encounters." Such programmes could also be a lever in the fight against stigmatisation with employers, the police or in clinics.
One example of contact-oriented anti-stigma work is the "BASTA" programme in schools at the DZPG site in Munich-Augsburg. At the contact seminars, the participating classes meet two members of the initiative: one who talks about their life with a mental illness, accompanied by a counsellor who moderates and provides expert advice. A scientific evaluation is now to determine whether such a programme reduces prejudice among pupils. This should also enable the programme to be developed for other population groups in the future. "Contact-based anti-stigma work is demonstrably effective," explains Rüsch.
Source: DZPG
Asthma in children is difficult to predict. However, a new risk score gives hope. Prof. Bianca Schaub from the German Centre for Lung Research (DZL) led a study combining molecular markers, epidemiological factors and allergic symptoms to provide a more precise prognosis.
Around a third of preschool children show asthma-like symptoms such as wheezing. Asthma develops later in 30 to 40 percent of these children. Early identification of children at risk is important to provide timely and personalised treatment and prevent serious chronic secondary diseases. Existing risk scores are often based on current symptoms such as early wheezing or allergic sensitisation and are poor at predicting childhood asthma.
Even at birth, genetic variants associated with an increased susceptibility to asthma can be identified in the umbilical cord blood. Epigenetic markers, such as chemical changes in the DNA, can also play a role in the development of asthma. Prof Schaub's team at the DZL site in Munich (CPC-M) developed a new risk score that combines these genetic markers with epidemiological markers such as gender and family history of asthma. They also included symptoms and diagnoses such as wheezing, atopic dermatitis and food allergies, significantly improving the predictive power. Researchers from the DZL site network BREATH also took part in the project. The results could be of great importance for clinical practice and future studies. Nevertheless, even this risk score is currently not sufficient to be used in practice.
Future studies could further analyse other factors, such as the composition of intestinal bacteria, metabolic products, and proteins in the body, to improve the accuracy of the predictions.
Original publication: An integrated molecular risk score early in life for subsequent childhood asthma risk. Böck, A., Urner, K., Eckert, J.K., et al. Clin Exp Allergy. 2024;54(5):314-328.
Quelle: DZL
You are currently viewing a placeholder content from Google Maps. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from OpenStreetMap. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Mapbox. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from hCaptcha to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from Turnstile to submit the form. Please note that doing so will share data with third-party providers.
More Information